The $2.4B Oral Macrocycle and Bispecific Surge: Why Big Pharma Is Buying Platform Engines Over Single Assets
Dr. Dereck Mush, MD, MBA
Plexium
Discovers targeted monovalent protein degraders using high-throughput cellular screening.
What they do
Plexium develops targeted protein degradation therapeutics using a high-throughput cell-based screening platform. The technology allows pharmaceutical researchers to identify small molecules, such as monovalent degraders and molecular glues, that selectively target and destroy disease-causing proteins.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Protein degradation
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- San Diego, USA
- Region
- North America
- Founded
- 2018
- Total funding
- $165M raised
Notable investors: BVF Partners, TCG Crossover, Amgen Ventures, Vertex Ventures.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
Bypassing Carrier Suppression: The 31-Valent Conjugate Architecture Reshaping Pneumococcal Vaccinology
Dr. Dereck Mush, MD, MBA